Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan with FOLFOX in Neoadjuvant Pancreatic Adenocarcinoma
NCT03483038Phase 2Active, not recruiting
- Sponsor
- University of Florida
- Start
- Dec 2018
- Primary completion
- Sep 2023
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan in pancreatic adenocarcinoma (PDAC), sponsored by University of Florida. Primary endpoint: Percentage of Subjects Who Had Post-operative Complications at 30 days. Started Dec 2018; status: active, not recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03483038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03483038.